Results 131 to 140 of about 939 (187)

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. [PDF]

Pain Manag
Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z.   +5 more
europepmc   +1 more source

Safety Profile of Zavegepant in the Treatment of Acute Migraine: Insights from the FDA Adverse Event Monitoring System Database. [PDF]

Pharmaceuticals (Basel)
Cicala G, Barbieri MA, Russo G, Ciurleo R, Grugno R, Quartarone A, Spina E.   +6 more
europepmc   +1 more source

Estimating risk of reported versus theoretical drug-drug interactions in headaches medicine: an exhaustive comparison between DrugBank and FAERS database for abortive and preventive combinations. [PDF]

J Oral Facial Pain Headache
Kaytser V, Hakkinen I, Dave J, Zhang P.
europepmc   +1 more source

The efficacy and safety of zavegepant nasal inhalation versus oral calcitonin-gene related peptide receptor antagonists in the acute treatment of migraine: a systematic review and network meta-analysis of the literature. [PDF]

J Headache Pain
Zhu Z, Tang Y, Li L, Ni H, Liu M, Chen Z, Wang Z.   +6 more
europepmc   +1 more source

Ubrogepant, erenumab, and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide in the isolated human atrium. [PDF]

Naunyn Schmiedebergs Arch Pharmacol
Neumann J, Hofmann B, Gergs U.
europepmc   +1 more source

Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. [PDF]

Headache
Ailani J, Lipton RB, Blumenfeld AM, Mechtler L, Klein BC, He MY, Smith JH, Trugman JM, de Abreu Ferreira R, Brand-Schieber E.   +9 more
europepmc   +1 more source

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series. [PDF]

Headache
Shah T, Dougherty C, Ailani J, Kerrigan T.   +3 more
europepmc   +1 more source

CGRP and Migraine: Real-World Insights and Future Therapeutic Directions. [PDF]

Annu Rev Med
Russo AF, Kaiser EA.
europepmc   +1 more source

A Case of Acute Migraine Without Aura Treated With a New FDA-Approved Medication Ubrogepant. [PDF]

Cureus
Shamsi MA, Khalid MA.
europepmc   +1 more source

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial. [PDF]

Neurology
Lipton RB, Harriott AM, Ma JY, Smith JH, Stokes J, Gandhi P, Jariwala-Parikh K, Jensen GS, Trugman JM, Dodick DW.   +9 more
europepmc   +1 more source